When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?
Answer from: at Academic Institution
As rheumatologists, we are accustomed to medical decision making in data free zones. This is what we face here too. There are no studies that have directly addressed these issues- nonetheless, the likelihood of meaningful drug interactions between a biological drug for RA and these various anti-vira...
Sign in or Register to read more